{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:30:24Z","timestamp":1775190624125,"version":"3.50.1"},"posted":{"date-parts":[[2024,12,13]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":51,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,12,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                    (pneumococcus) causes invasive pneumococcal disease (IPD) and non-invasive acute respiratory infections (ARIs). Three pneumococcal conjugate vaccines (PCVs) are recommended in the United States with additional products in clinical trials. We aimed to estimate 1) proportions of IPD cases and pneumococcal ARIs caused by serotypes targeted by existing and pipeline PCVs and 2) annual U.S. pneumococcal burdens potentially preventable by PCVs.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We estimated serotype distribution and proportions of non-invasive pneumococcal ARIs (AOM [children only], sinusitis, non-bacteremic pneumonia) and IPD attributable to serotypes targeted by each PCV using Markov chain Monte Carlo approaches incorporating data from studies of serotype distribution in ARIs and Active Bacterial Core Surveillance (ABCs) data. We then estimated annual numbers of outpatient-managed pneumococcal ARIs, non-bacteremic pneumococcal pneumonia hospitalizations, and IPD cases potentially preventable by PCVs in the United States by multiplying pneumococcal disease incidence rates by PCV-targeted proportions of disease and vaccine effectiveness estimates.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In children, PCV15, PCV20, PCV24, PCV25, and PCV31 serotypes account for 16% (95% confidence interval: 15\u201317%), 31% (30\u201332%), 34% (32\u201335%), 43% (42\u201344%), and 68% (67\u201369%) of pneumococcal acute otitis media cases, respectively. In adults, PCV15, PCV20, PCV21, PCV24, PCV25, and PCV31 serotypes account for 43% (38\u201347%), 52% (47\u201357%), 69% (64\u201373%), 65% (61\u201370%), 62% (57\u201367%), and 87% (83\u201390%) of pneumococcal non-bacteremic pneumonia cases. For IPD, 42\u201385% of pediatric and 42\u201394% of adult cases were due to PCV-targeted serotypes. PCV-preventable burdens encompassed 270 thousand\u20133.3 million outpatient-managed ARIs, 2\u201317 thousand non-bacteremic pneumonia hospitalizations, and 3\u201314 thousand IPD cases in the United States annually.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Across pneumococcal conditions, coverage and preventable burdens were lowest for PCV15 and highest for PCV31, with PCV21 also targeting sizeable burdens of adult disease. Serotype distribution across syndromes may inform vaccine formulations and policy.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.12.12.24318944","type":"posted-content","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T15:22:01Z","timestamp":1734103321000},"source":"Crossref","is-referenced-by-count":5,"title":["PNEUMOCOCCAL SEROTYPE DISTRIBUTION AND COVERAGE OF EXISTING AND PIPELINE PNEUMOCOCCAL VACCINES"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-4712","authenticated-orcid":false,"given":"Laura M","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin L","family":"Andrejko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miwako","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam L","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wesley H","family":"Self","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Jackson","family":"Resser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia G","family":"Whitney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Kio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos G","family":"Grijalva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Traenkner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A","family":"Lewnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024121602200855000_2024.12.12.24318944v1.1","unstructured":"Blacklock CB , Weinberger DM , Perniciaro S , Wyllie AL. Streptococcus pneumoniae serotypes. Published online 2024. https:\/\/pneumococcalcapsules.github.io\/serotypes\/"},{"key":"2024121602200855000_2024.12.12.24318944v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.09.008"},{"key":"2024121602200855000_2024.12.12.24318944v1.3","unstructured":"Centers for Disease Control and Prevention. Bact Facts: Streptococcus pneumoniae. Accessed March 8, 2022. https:\/\/app.powerbigov.us\/view?r=eyJrIjoiNjc5OGRjODctNWQ5ZC00ZWEwLWI5ZjgtNGI3ZmFhODVmYTlhIiwidCI6IjljZTcwODY5LTYwZGItNDRmZC1hYmU4LWQyNzY3MDc3ZmM4ZiJ9&pageName=ReportSectione93482d78e7dc3ed111b"},{"key":"2024121602200855000_2024.12.12.24318944v1.4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa66"},{"key":"2024121602200855000_2024.12.12.24318944v1.5","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2021.230"},{"key":"2024121602200855000_2024.12.12.24318944v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102083440602"},{"key":"2024121602200855000_2024.12.12.24318944v1.7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1164"},{"key":"2024121602200855000_2024.12.12.24318944v1.8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac098"},{"key":"2024121602200855000_2024.12.12.24318944v1.9","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7239a5"},{"key":"2024121602200855000_2024.12.12.24318944v1.10","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7137a3"},{"key":"2024121602200855000_2024.12.12.24318944v1.11","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7203a1"},{"key":"2024121602200855000_2024.12.12.24318944v1.12","unstructured":"Centers for Disease Control and Prevention. ACIP Recommendations. Advisory Committee on Immunization Practices (ACIP). October 25, 2024. Accessed October 25, 2024. https:\/\/www.cdc.gov\/acip\/vaccine-recommendations\/index.html"},{"key":"2024121602200855000_2024.12.12.24318944v1.13","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz178"},{"key":"2024121602200855000_2024.12.12.24318944v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62225-8"},{"key":"2024121602200855000_2024.12.12.24318944v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30660-1"},{"key":"2024121602200855000_2024.12.12.24318944v1.16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1860"},{"key":"2024121602200855000_2024.12.12.24318944v1.17","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00329-21"},{"key":"2024121602200855000_2024.12.12.24318944v1.18","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs). June 11, 2024. Accessed September 18, 2024. https:\/\/www.cdc.gov\/abcs\/about\/index.html"},{"key":"2024121602200855000_2024.12.12.24318944v1.19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae316"},{"key":"2024121602200855000_2024.12.12.24318944v1.20","unstructured":"US Food & Drug Administration. CAPVAXIVE. Published online July 17, 2024. Accessed October 17, 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/capvaxive"},{"key":"2024121602200855000_2024.12.12.24318944v1.21","unstructured":"Merck Sharp & Dohme LLC. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease. clinicaltrials.gov; 2024. Accessed October 17, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06177912"},{"key":"2024121602200855000_2024.12.12.24318944v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.04.061"},{"key":"2024121602200855000_2024.12.12.24318944v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.056"},{"key":"2024121602200855000_2024.12.12.24318944v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.03.065"},{"key":"2024121602200855000_2024.12.12.24318944v1.25","unstructured":"Self WH . Interim Results from the PNEUMO Study. Presented at: Advisory Committee on Immunization Practices; February 29, 2024; Atlanta, GA. Accessed April 2, 2024. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2024-02-28-29\/03-Pneumococcal-Self-508.pdf"},{"key":"2024121602200855000_2024.12.12.24318944v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.06.041"},{"key":"2024121602200855000_2024.12.12.24318944v1.27","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1560"},{"key":"2024121602200855000_2024.12.12.24318944v1.28","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus Pneumoniae, 2019. Centers for Disease Control and Prevention; 2021. Accessed June 27, 2024. https:\/\/www.cdc.gov\/abcs\/downloads\/spn_surveillance_report_2019.pdf"},{"key":"2024121602200855000_2024.12.12.24318944v1.29","unstructured":"HCUP-US NIS Overview. Accessed June 26, 2024. https:\/\/hcup-us.ahrq.gov\/nisoverview.jsp"},{"key":"2024121602200855000_2024.12.12.24318944v1.30","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae142"},{"key":"2024121602200855000_2024.12.12.24318944v1.31","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa529"},{"key":"2024121602200855000_2024.12.12.24318944v1.32","unstructured":"Centers for Disease Control and Prevention. 2019 NAMCS MICRO-DATA FILE DOCUMENTATION. Accessed June 26, 2024. https:\/\/ftp.cdc.gov\/pub\/Health_Statistics\/NCHS\/Dataset_Documentation\/NAMCS\/doc2019-508.pdf"},{"key":"2024121602200855000_2024.12.12.24318944v1.33","unstructured":"Centers for Disease Control and Prevention. Bridged-Race Population Estimates -Data Files and Documentation. November 5, 2021. Accessed June 12, 2023. https:\/\/www.cdc.gov\/nchs\/nvss\/bridged_race\/data_documentation.htm"},{"key":"2024121602200855000_2024.12.12.24318944v1.34","unstructured":"ACIP Vaccine Recommendations and Schedules. June 28, 2024. Accessed September 11, 2024. https:\/\/www.cdc.gov\/vaccines\/acip\/recommendations.html"},{"key":"2024121602200855000_2024.12.12.24318944v1.35","doi-asserted-by":"crossref","unstructured":"Lucero MG , Dulalia VE , Parre\u00f1o RAN , et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age -Lucero, MG -2004 | Cochrane Library. Accessed September 18, 2024. https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD004977\/full","DOI":"10.1002\/14651858.CD004977"},{"key":"2024121602200855000_2024.12.12.24318944v1.36","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1867"},{"key":"2024121602200855000_2024.12.12.24318944v1.37","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1860"},{"key":"2024121602200855000_2024.12.12.24318944v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.03.045"},{"key":"2024121602200855000_2024.12.12.24318944v1.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408544"},{"key":"2024121602200855000_2024.12.12.24318944v1.40","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000004334"},{"key":"2024121602200855000_2024.12.12.24318944v1.41","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab990"},{"key":"2024121602200855000_2024.12.12.24318944v1.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1307228110"},{"key":"2024121602200855000_2024.12.12.24318944v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00572-8"},{"key":"2024121602200855000_2024.12.12.24318944v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.07.025"},{"key":"2024121602200855000_2024.12.12.24318944v1.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.05.079"},{"key":"2024121602200855000_2024.12.12.24318944v1.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.02.001"},{"key":"2024121602200855000_2024.12.12.24318944v1.47","unstructured":"Platt H. V116: An Investigational Adult Specific Pneumococcal Conjugate Vaccine. Presented at: Advisory Committee on Immunization Practices Meeting; February 29, 2024; Atlanta, GA. Accessed June 27, 2024. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2024-02-28-29\/04-Pneumococcal-Platt-508.pdf"},{"key":"2024121602200855000_2024.12.12.24318944v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.10.054"},{"key":"2024121602200855000_2024.12.12.24318944v1.49","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00344-X"},{"key":"2024121602200855000_2024.12.12.24318944v1.50","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa501"},{"key":"2024121602200855000_2024.12.12.24318944v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.05.065"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.12.12.24318944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:22:50Z","timestamp":1768508570000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.12.12.24318944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1101\/2024.12.12.24318944","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1093\/infdis\/jiaf376","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,12,13]]},"subtype":"preprint"}}